Peptide-mediated disruption of calmodulin-cyclin e interactions inhibits proliferation of vascular smooth muscle cells and neointima formation

Circulation Research

Volumn 108, Issue 9, 2011, Pages 1053-1062

  Hui, Sonya ^a,d   Choi, Jaehyun ^a,c   Zaidi, Syed ^a,d   Momen, Abdul ^a   Steinbach, Sarah K ^a   Sadi, Al Muktafi ^a   Ban, Kiwon ^a,d   Husain, Mansoor ^a,b,c,d  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b Heart and Stroke Richard Lewar Centre of Excellence in Cardiovascular Research   (Canada)

^c University of Tokyo   (Japan)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

calmodulin; cell cycle; cyclin E CDK2; restenosis; vascular smooth muscle cell

Indexed keywords

CALCIUM ION; CALMODULIN; CALMODULIN BINDING SEQUENCE PEPTIDE; COLLAGEN; CYCLIN DEPENDENT KINASE 2; CYCLIN E; HISTONE H1; PEPTIDE; TRANSACTIVATOR PROTEIN; TRANSGELIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; AORTA; ARTICLE; CAROTID ARTERY INJURY; CAROTID ARTERY OBSTRUCTION; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL PROLIFERATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NEOINTIMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SMOOTH MUSCLE FIBER; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE;

EID: 85027919729     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.110.239483     Document Type: Article

References (34)

1. Dzau VJ, Braun-Dullaeus RC, Sedding DG. Vascular proliferation and atherosclerosis: new perspectives and therapeutic strategies. Nat Med. 2002;8:1249-1256. (Pubitemid 35373556)
2. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362:801-809. (Pubitemid 23132154)
3. Kahl CR, Means AR. Regulation of cell cycle progression by calcium/ calmodulin-dependent pathways. Endocr Rev. 2003;24:719-736. (Pubitemid 38067696)
4. Husain M, Bein K, Jiang L, Alper SL, Simons M, Rosenberg RD. c-Myb-dependent cell cycle progression and Ca2+ storage in cultured vascular smooth muscle cells. Circ Res. 1997;80:617-626. (Pubitemid 27181344)
5. Husain M, Jiang L, See V, Bein K, Simons M, Alper SL, Rosenberg RD. Regulation of vascular smooth muscle cell proliferation by plasma membrane Ca(2+)-ATPase. Am J Physiol. 1997;272:C1947-C1959.
6. Afroze T, Yang LL, Wang C, Gros R, Kalair W, Hoque AN, Mungrue IN, Zhu Z, Husain M. Calcineurin-independent regulation of plasma membrane Ca2+ ATPase-4 in the vascular smooth muscle cell cycle. Am J Physiol Cell Physiol. 2003;285:C88-C95. (Pubitemid 36736340)
7. Gros R, Afroze T, You XM, Kabir G, Van Wert R, Kalair W, Hoque AE, Mungrue IN, Husain M. Plasma membrane calcium ATPase overexpression in arterial smooth muscle increases vasomotor responsiveness and blood pressure. Circ Res. 2003;93:614-621. (Pubitemid 37222157)
8. Choi J, Chiang A, Taulier N, Gros R, Pirani A, Husain M. A calmodulin- binding site on cyclin E mediates Ca2+-sensitive G1/S transitions in vascular smooth muscle cells. Circ Res. 2006;98:1273-1281. (Pubitemid 43948082)
9. Choi J, Husain M. Calmodulin-mediated cell cycle regulation: new mechanisms for old observations. Cell Cycle. 2006;5:2183-2186. (Pubitemid 44546549)
10. Legrand C, Bour JM, Jacob C, Capiaumont J, Martial A, Marc A, Wudtke M, Kretzmer G, Demangel C, Duval D, et al. Lactate dehydrogenase (LDH) activity of the cultured eukaryotic cells as marker of the number of dead cells in the medium [corrected]. J Biotechnol. 1992;25:231-243.
11. You XM, Mungrue IN, Kalair W, Afroze T, Ravi B, Sadi AM, Gros R, Husain M. Conditional expression of a dominant-negative c-Myb in vascular smooth muscle cells inhibits arterial remodeling after injury. Circ Res. 2003;92:314-321. (Pubitemid 36258554)
12. Denizot F, Lang R. Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J Immunol Methods. 1986;89:271-277. (Pubitemid 16080782)
13. Geng Y, Yu Q, Sicinska E, Das M, Schneider JE, Bhattacharya S, Rideout WM, Bronson RT, Gardner H, Sicinski P. Cyclin E ablation in the mouse. Cell. 2003;114:431-443. (Pubitemid 37100992)
14. Wadia JS, Dowdy SF. Transmembrane delivery of protein and peptide drugs by TAT-mediated transduction in the treatment of cancer. Adv Drug Deliv Rev. 2005;57:579-596. (Pubitemid 40255562)
15. Nagahara H, Vocero-Akbani AM, Snyder EL, Ho A, Latham DG, Lissy NA, Becker-Hapak M, Ezhevsky SA, Dowdy SF. Transduction of fulllength TAT fusion proteins into mammalian cells: TAT-p27Kip1 induces cell migration. Nat Med. 1998;4:1449-1452. (Pubitemid 28553472)
16. Dong LH, Wen JK, Liu G, McNutt MA, Miao SB, Gao R, Zheng B, Zhang H, Han M. Blockade of the Ras-extracellular signal-regulated kinase 1/2 pathway is involved in smooth muscle 22 alpha-mediated suppression of vascular smooth muscle cell proliferation and neointima hyperplasia. Arterioscler Thromb Vasc Biol. 2010;30:683-691.
17. Kibbe MR, Billiar TR, Tzeng E. Gene therapy for restenosis. Circ Res. 2000;86:829-833. (Pubitemid 30246978)
18. Dangas G, Kuepper F. Cardiology patient page. Restenosis: repeat narrowing of a coronary artery: prevention and treatment. Circulation. 2002; 105:2586-2587. (Pubitemid 34596031)
19. Serruys PW, Luijten HE, Beatt KJ, Geuskens R, de Feyter PJ, van den Brand M, Reiber JH, ten Katen HJ, van Es GA, Hugenholtz PG. Incidence of restenosis after successful coronary angioplasty: a time-related phenomenon. A quantitative angiographic study in 342 consecutive patients at 1, 2, 3, and 4 months. Circulation. 1988;77:361-371. (Pubitemid 18060045)
20. Greenberg D, Bakhai A, Cohen DJ. Can we afford to eliminate restenosis? Can we afford not to? J Am Coll Cardiol. 2004;43:513-518. (Pubitemid 38229518)
21. Hoffmann R, Mintz GS, Dussaillant GR, Popma JJ, Pichard AD, Satler LF, Kent KM, Griffin J, Leon MB. Patterns and mechanisms of in-stent restenosis. A serial intravascular ultrasound study. Circulation. 1996;94: 1247-1254. (Pubitemid 26307249)
22. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, Colombo A, Schuler G, Barragan P, Guagliumi G, Molnar F, Falotico R. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002; 346:1773-1780. (Pubitemid 34586912)
23. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, Popma JJ, Russell ME. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med. 2004;350:221-231. (Pubitemid 38067635)
24. Junker JP, Rief M. Single-molecule force spectroscopy distinguishes target binding modes of calmodulin. Proc Natl Acad Sci USA. 2009; 106:14361-14366.
25. Urbich C, Dimmeler S. Endothelial progenitor cells: characterization and role in vascular biology. Circ Res. 2004;95:343-353. (Pubitemid 39100452)
26. Kim S, Lin H, Barr E, Chu L, Leiden JM, Parmacek MS. Transcriptional targeting of replication-defective adenovirus transgene expression to smooth muscle cells in vivo. J Clin Invest. 1997;100:1006-1014. (Pubitemid 27386284)
27. Baker AH. Development and use of gene transfer for treatment of cardiovascular disease. J Card Surg. 2002;17:543-548. (Pubitemid 36308371)
28. Kreppel F, Kochanek S. Modification of adenovirus gene transfer vectors with synthetic polymers: a scientific review and technical guide. Mol Ther. 2008;16:16-29.
29. Beck C, Uramoto H, Boren J, Akyurek LM. Tissue-specific targeting for cardiovascular gene transfer. Potential vectors and future challenges. Curr Gene Ther. 2004;4:457-467. (Pubitemid 39534759)
30. Toogood PL. Inhibition of protein-protein association by small molecules: approaches and progress. J Med Chem. 2002;45:1543-1558. (Pubitemid 34293520)
31. Yu H, Sliedregt-Bol K, Overkleeft H, van der Marel GA, van Berkel TJ, Biessen EA. Therapeutic potential of a synthetic peptide inhibitor of nuclear factor of activated T cells as antirestenotic agent. Arterioscler Thromb Vasc Biol. 2006;26:1531-1537.
32. Chen YN, Sharma SK, Ramsey TM, Jiang L, Martin MS, Baker K, Adams PD, Bair KW, Kaelin WG Jr. Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists. Proc Natl Acad Sci USA. 1999;96:4325-4329. (Pubitemid 29190335)
33. Levin RM, Weiss B. Inhibition by trifluoperazine of calmodulin-induced activation of ATPase activity of rat erythrocyte. Neuropharmacology. 1980;19:169-174. (Pubitemid 10143779)
34. Orner BP, Ernst JT, Hamilton AD. Toward proteomimetics: terphenyl derivatives as structural and functional mimics of extended regions of an alpha-helix. J Am Chem Soc. 2001;123:5382-5383. (Pubitemid 32910693)